The IPO tide continues! Ten more pharmaceutical companies have filed for a U.S. stock market listing

The global new crown pandemic does not seem to have slowed the IPO process of pharmaceutical companies, just past 2020 has set off a wave of listings, according to relevant statistics, the United States, A-shares and Hong Kong stocks in the three major stock markets have more than 100 biopharmaceutical companies successfully IPO.
and when it comes to 2021, the global boom will continue.
2021, Cullinan Oncology, a biopharmaceutical company focused on the development of transformative targeting and immunotherapy for cancer patients in the United States, has successfully listed on NASDAQ and kicked off the new year's IPO of a biopharmaceutical company.
So far, ten companies have filed applications for U.S. listings, including China's Tianding Pharmaceuticals, and the following are the specifics of the ten companies for reference: 1Sana Biotechnology CEO: Steve Harr Stock Code: SANA Filing Date: 2021.1.12 Estimated Financing: $150 million Company Profile: Sana's expected $150 million, but they may want a bigger number when they end up in the public market.
as a participant in the cell therapy 2.0 era, their ultimate goal is far from unicorns, and their final market value could be between $9 and $12 billion.
this size, if compared with Moderna, which had a market capitalisation of $7.5bn at the start of the market, soared to more than $50bn as research and development of the new crown vaccine was heavily supported.
Sana is not yet able to reach this scale.
current high valuations are based entirely on the company's animal data and investor track record.
Sana's long-term goal, as it states, is to "repair and control genes in any cell, replace any damaged or missing cells, and significantly improve access to cell-based and gene-based drugs."
is expected to submit its first INDs in 2022 and 2023 and is studying a range of adaptations, including non-Hodgkin's lymphoma, multiple myeloma and type 1 diabetes, both in vivo and in ionoid environments.
2Sensei Biotherapeutics CEO: John Celebi Stock Code: SNSE Submission Date: 2021.1.15 Estimated Fundraising: $100 million Company Profile: Sensei, formerly known as Panacea, was founded in 1999 in Rockville, Md., as a phase II clinical biopharmaceutical company developing bacterial-based phage therapy for cancer.
plans to raise $100 million.
the company's leading candidate is SNS-301, which targets cancer antigen Aspartyl beta hydroxygenase (ASPH) in a joint treatment for head and neck squamous cell carcinoma with Merck's Keytruda.
as of December 10, 2020, 11 patients had been recruited for the Phase I/II trial.
7 out of 10 assessable patients can see some form of disease control, with 1 patient partially remission and 2 patients able to maintain long-term stability.
hopes to read key data by the end of 2021 and pave the way for the launch of the registration trial.
months before the IPO, Sensei received its $28.5 million AA round of financing.
Sensei has also developed two preclinical drug candidates: SNS-401, a potential vaccine mixture for Merkel's cell carcinoma, and SNS-VISTA, an antibody-based treatment.
3Bolt Biotherapeutics CEO: Randy Schatzman Stock Code: BOLT Submission Date: 2021.1.15 Estimated Fundraising: $100 million Company Profile: Bolt is a biotech company for solid tumors, founded in 2015 by Dr. Edgar G. Engleman of Stanford University and headquartered in California, USA.
company's candidate drug, BDC-1001, is a HER2 bolt antibody immunostational antibody association drug.
in preclinical safety studies, the BDC-1001 was well-to-do and no adverse safety signals were observed.
BDC-1001 is currently in Phase I/II clinical trials for the treatment of patients with solid tumors expressing HER2, and the company is expected to enter the Phase II dose expansion phase of critical solid tumor adaptation in 2021.
the first batch of data from the study, it will go into trials specifically targeting stomach and breast cancer.
Bort's most recent financing was in July last year, when Round C raised $93.5 million.
4Terns Pharmaceuticals CEO: Senthil Sundaram Stock Code: TERN Filing Date: 2021.1.15 Estimated Fundraising: $100 million Company Profile: Terns was founded in 2016 and is headquartered in California, USA, as a Phase II biotechnology company developing small molecule therapies for NASH (non-alcoholic fatty hepatitis).
just received $87.5 million in round C financing in early January.
the main drug candidate for Terns is TERN-101, a Farnesoid X-subject (FXR) astrogen, which is currently undergoing phase IIa trials.
is expected to generate significant IIa data in the second half of 2021.
Terns faces competition from other NASH players, such as Intercept and AbbVie, which took over FXR in allergan takeovers, but the company believes the safety of candidates is paramount.
Terns' prospectus also details plans to complete the first phase of the candidate drug TERN-501 program and launch Phase II development, and to advance the research and development program for the third drug candidate drug, TerN-201, through phase IB.
5Immunocore CEO: Bahija Jallal Stock Code: IMCR Submission Date: 2021.1.15 Estimated Fundraising: $100 million Company Profile: TCR (Antigen Subject) Pioneer Immunocore was founded in 2008 and is headquartered in Abingdon, UK, as a clinical biotech company.
disclosed a promising set of key interim data for its lead project, tebentafusp, in November and aims to use IPO funds to complete the third phase of the candidate's research into first-line metastasis cases of serotonin melanoma.
there is currently no approved treatment for first-line metastasis staphylococcal melanoma, so patients usually choose between Keytruda or Yervoy, and some patients choose dacarbazine.
in the first planned medium-term reading for intentional treatment for all patients, The Risk Ratio of Immunocore was 0.51.
Jallal told Endpoints News at the time that this was not only the first positive late-stage survival data for TCR, but also the first phase III positive snapshot of dual-specific antibodies in solid tumors and the first such match for checkpoints.
has raised more than $450 million in the past, including $320 million in round A financing in 2015, when it set a European record.
6Vor Biopharma CEO: Robert Ang Stock Code: VOR Filing Date: 2021.1.15 Estimated Fundraising: $150 million Company Profile: Vor was founded in 2015 and is headquartered in Massa, USA, as a biotech in the clinical phase of Phase I/II for the development of cell therapies for blood diseases.
the company's IPO goal is to raise money for its VOR33 and VCAR33 research and development programs, hoping they will work together.
VOR33 is an engineering hematopoietic stem cell designed to replace the standard of care in a transplant environment, and once these cells are implanted, Vor says it can treat patients with anti-CD33 therapies, such as VCAR33.
Vor currently plans to begin VOR33's Phase I/IIa trial in acute myeloid leukemia in the first half of this year, and the funds raised will also be used for preclinical development of bone marrow growth abnormalities/bone marrow growth tumors.
Vor is seeking to fund Phase I/II clinical trials for the CD33-guided CAR-T cell therapy VCAR33, which was approved by the National Institutes of Health (NIH) last November.
the biotech company has received huge capital support after completing two rounds of $152 million financing led by RA Capital.
7Pharvaris CEO: Berndt Modig Stock Code: PHVS Submission Date: 2021.1.15 Estimated Fundraising: $100 million Company Profile: Pharvaris was founded in 2015 and is headquartered in the Netherlands and is a clinical phase company.
started hitting Nasdaq last November after raising $80m in round C financing.
their pilot program is an inhibitor and selective small molecule refraction peptide B2 inhibitor, which is currently being used as an oral alternative to oral HAE (genetic angioedema) treatment, and is now available to include injectable CSL Haegarda, Takeda's Cinryze, Takhzyro and Firazyr.
and the team came from Jerini, the biotech company that originally developed Fiazyr.
as early as November, the company obtained Phase I data from 16 healthy volunteers, saying its molecules were 24 times more potency than the drug.
Pharvaris is launching two Phase II trials, one for prevention and the other for the treatment of acute HAE seizures.
if successful, they will conduct an important Phase III study.
and plans to read Phase II data for acute patients in 2022.
, the company is developing a new preparation that will eventually be used in preventive trials.
, Pharvaris may face challenges as other companies on the market have struggled to develop oral HAE treatments in the past.
8-Day Performance Pharmaceutical CEO: ADAG Submission Date: 2021.1.19 Estimated Fundraising: $126 million Company Profile: As a bioantibody drug developer, Tianpei Pharmaceuticals is committed to developing a new generation of therapeutic and diagnostic antibody technology drugs that can design and produce the antibodies needed by humans and reduce the costs associated with the development of therapeutic antibodies through self-developed intelligent antibody technologies.
present, Tianying Pharmaceuticals has established an antibody research and development platform with independent intellectual property rights - Dynamic Precision Antibody Library (DPL), deep layout of tumor immunity and the development of targeted therapeutic drugs.
days in the study of three core products ADG106, ADG116, ADG126, which is used to treat advanced solid tumors, non-Hodgkin's lymphoma or NHL ADG106 is in clinical trials in China and the United States, has been observed to have good anti-tumor activity and tolerance, the most promising commercialization.
another product, ADG126, aims to address the toxicity and efficacy of MOA associated with existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for cancer treatment.
product has now been approved by the FDA and will be used in Phase I clinical trials in the United States this year.
According to its prospectus, Tianding Pharmaceuticals plans to use the funds raised by Tianding Pharmaceuticals to use 95% of the net proceeds of the offering to advance trials of drug candidates, of which about 26% will be used for the first phase of the ADG106 trial and the progress of phase II trials; 26% of the funds were spent on ADG126 and ADG116; 43% on the company's technology and platform development and the development of preclinical drug candidates; and the remaining approximately 5% was spent on working capital and other general corporate purposes.
9NexImmune CEO: Scott Carmer Stock Code: NEXI Submission Date: 2021.1.19 Estimated Fundraising: $86 million Company Profile: NexImmune was founded in 2011 and is headquartered in Maryland, USA, as a clinical biopharmaceutical company that is advancing a new generation of immunotherapy based on proprietary artificially regulated nanotechnology platforms.
the company's most recent financing in 2019, received $7.8 million in wind investments.
, however, the company has maintained a low profile, and researchers released preliminary results of the Phase I/II study in december's ASH Leadership Program.
study is being evaluated in patients with acute myeloid leukemia for NEXI-001.
in the first five patients, the results indicated that absolute lymphocyte counts could be restored to baseline levels within 3 to 35 days.
, the program is still in its early clinical stages, with the goal of recruiting 22 to 28 patients.
NEXI-002, another major candidate for NexImmune, has yet to be read, but the first case of multiple myeloma was given in October last year.
Ismmune is currently in the security assessment phase of two trials, and IPO funds will be used for both programs.
10 Biophytis CEO: Stanislas Veillet Stock Code: BPTS Submission Date: 2021.1.19 Estimated Fundraising: $15 million Company Profile: Biophytis was founded in 2006 and is headquartered in France as a clinical biotechnology company.
the company is filing for an IPO for the second time since 2019